Riskpilot← Back to searchSign inGet full accessPCI BIOTECH AS
ASIn liquidationOrg 982611830Ullernchausséen 64, 0379 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20005 employeeswww.pcibiotech.no
Revenue 2024
NOK 6,7M
+125% vs 2023
EBITDA margin
-203.8%
+22% vs 2023
Equity ratio
78.4%
Financial strength
Net profit 2024
NOK -12,4M
+24% vs 2023
| Revenue | NOK 6,7M | +125% |
| EBITDA | NOK -13,7M | +22% |
| Net profit | NOK -12,4M | +24% |
| Total assets | NOK 31,5M | -27% |
| Equity | NOK 24,7M | -32% |
| Employees | 5 | — |
Legal name
PCI BIOTECH AS
Org number
982611830
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21. desember 2000
Share capital
NOK 323 260
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Utgår
Company purpose
Drive forretningsmessig virksomhet innenfor bioteknologisk basert diagnostikk, behandling og tilgrensende områder, og alt hva dermed står i forbindelse.
Address
Ullernchausséen 64, 0379 Oslo
Phone
+4767115400
Email
post@pcibiotech.no
Website
www.pcibiotech.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 7 368 | 6 273 | 4 750 | 2 990 | 6 735 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −77 457 | −81 060 | −51 225 | −17 605 | −13 727 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −77 457 | −81 060 | −51 225 | −17 605 | −13 727 |
| Net financials | −1 211 | −1 233 | −369 | 1 404 | 1 361 |
| Profit before tax | −78 668 | −82 293 | −51 594 | −16 201 | −12 366 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −78 668 | −82 293 | −51 594 | −16 201 | −12 366 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 140 562 | 109 469 | 62 830 | 43 001 | 31 534 |
| Equity | 102 748 | 73 393 | 50 506 | 36 260 | 24 723 |
| Long-term debt | 32 | 1 277 | 327 | 34 | 0 |
| Short-term debt | 37 783 | 34 799 | 11 998 | 6 707 | 6 812 |
| Total debt | 37 815 | 36 076 | 12 325 | 6 741 | 6 812 |
EBITDA margin
-203.8%
This company
15.8%
Market median
-1390% vs market
20202024
Equity ratio
78.4%
This company
38.2%
Market median
+105% vs market
20202024
Return on equity
-50.0%
This company
18.4%
Market median
-372% vs market
20202024
Net profit margin
-183.6%
This company
8.1%
Market median
-2367% vs market
20202024
Asset turnover
0.21×
This company
1.12×
Market median
-81% vs market
20202024
Debt / equity
0.28×
This company
0.62×
Market median
+55% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Chairman | 2022 | |
| Chairman | 2025 | |
| Board of Directors | 2022 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2022 | |
| Former (2) | ||
| Board of Directors | 2022 – 2022 | |
| Chairman | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Myrlid As
PCI BIOTECH AS Board members of PCI BIOTECH AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ronny Skuggedal | Chairman | 0 companies |
| Hans Peter Bøhn | Chairman | 0 companies |
| Lucy Mette Wabakken | Board of Directors | 0 companies |
| Anders Høgset | Board of Directors | 0 companies |
| Lars Kåre Viksmoen | Board of Directors | 0 companies |
| Per Edvard Walday | Chairman | 0 companies |
| Hilde Furberg | Board of Directors | 0 companies |
| Karin Nord | Board of Directors | 0 companies |